Full text

Turn on search term navigation

© 2019. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Novel diagnostic and prognostic biomarkers of cancers are needed to improve precision medicine. Circular RNAs act as important regulators in cancers at the transcriptional and posttranscriptional levels. The circular RNA circMAN1A2 is highly expressed in nasopharyngeal carcinoma according to our previous RNA sequencing data; however, the expression and functions of circMAN1A2 in cancers are still obscure. Therefore, in this study, we evaluated the expression of circMAN1A2 in the sera of patients with nasopharyngeal carcinoma and other malignant tumors and analyzed its correlations with clinical features and diagnostic values. The expression levels of circMAN1A2 were detected by quantitative real‐time PCR, and the correlations of clinical features with circMAN1A2 expression were analyzed by χ2 tests. Receiver operating characteristic curves were used to evaluate the clinical applications of circMAN1A2. The results showed that circMAN1A2 was upregulated in nasopharyngeal carcinoma, oral cancer, thyroid cancer, ovarian cancer, and lung cancer, with areas under the curves of 0.911, 0.779, 0.734, 0.694, and 0.645, respectively, indicating the good diagnostic value of circMAN1A2. Overall, our findings suggested that circMAN1A2 could be a serum biomarker for malignant tumors, providing important insights into diagnostic approaches for malignant tumors. Further studies are needed to elucidate the mechanisms of circMAN1A2 in the pathogenesis of cancer.

Details

Title
circ MAN 1A2 could serve as a novel serum biomarker for malignant tumors
Author
Chun‐Mei Fan 1 ; Jin‐Peng Wang 2 ; Yan‐Yan Tang 2 ; Zhao, Jin 2 ; Shu‐Yi He 2 ; Xiong, Fang 3 ; Guo, Can 2 ; Xiang, Bo 2 ; Zhou, Ming 2   VIAFID ORCID Logo  ; Xiao‐Ling Li 2 ; Li, Yong 4 ; Gui‐Yuan Li 1 ; Xiong, Wei 1   VIAFID ORCID Logo  ; Zhao‐Yang Zeng 1 

 NHC Key Laboratory of Carcinogenesis, Xiangya Hospital, Central South University, Changsha, China; The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, China; Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Disease Genome Research Center, The Third Xiangya Hospital, Central South University, Changsha, China 
 The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, China 
 NHC Key Laboratory of Carcinogenesis, Xiangya Hospital, Central South University, Changsha, China 
 The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, China; Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA 
Pages
2180-2188
Section
ORIGINAL ARTICLES
Publication year
2019
Publication date
Jul 2019
Publisher
John Wiley & Sons, Inc.
ISSN
13479032
e-ISSN
13497006
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2405793714
Copyright
© 2019. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.